rivaroxaban + dabigatran etexilate + clarithromycin

This combination regimen refers to the sequential and concurrent administration of **rivaroxaban**, **dabigatran etexilate**, and **clarithromycin** as studied in the "DRIVING" clinical trial (NCT01442207) sponsored by **Assistance Publique - Hôpitaux de Paris**. Rivaroxaban is a direct Factor Xa inhibitor, and dabigatran etexilate is a prodrug of dabigatran, a direct thrombin inhibitor; both are used for the prevention and treatment of **thromboembolism**. Clarithromycin, a macrolide antibiotic, was included in this specific protocol to act as an inhibitor of **P-glycoprotein (P-gp)** and **CYP3A4**, allowing researchers to investigate the impact of genetic variations (such as *ABCB1* polymorphisms) on the intestinal absorption and overall pharmacokinetics of these new oral anticoagulants (NOACs).

Other names

r + d + c + d